Request Demo
Last update 14 Apr 2025
Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Last update 14 Apr 2025
Overview
Basic Info
Drug Type Therapeutic vaccine, Multivalent vaccine |
Synonyms- |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)CTR20222643
多中心、随机、双盲、安慰剂对照评估四价重组人乳头瘤病毒疫苗（汉逊酵母）接种于18-45岁中国女性预防HPV6/11/16/18型感染相关下生殖道病变的保护效力、免疫原性和安全性的III期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, immunogenicity and safety of quadrivalent recombinant human papillomavirus vaccine (Hansen yeast) in preventing lower genital tract lesions associated with HPV6/11/16/18 infection in Chinese women aged 18-45 years
NCT05584332
A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
CTR20221050
评价四价重组人乳头瘤病毒（6/11/16/18 型）疫苗（汉逊酵母）接种于9-45 岁中国女性免疫持久性的开放性临床试验
[Translation] An open-label clinical trial to evaluate the immune persistence of quadrivalent recombinant human papillomavirus (types 6/11/16/18) vaccine (Hansenella spp.) in Chinese women aged 9-45 years
100 Clinical Results associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Login to view more data
100 Translational Medicine associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Login to view more data
100 Patents (Medical) associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Login to view more data
5
Literatures (Medical) associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)01 Jan 2025Vaccine: X
Cervical Cancer and HPV vaccination: Insights into knowledge, attitudes, and practices among Albanian women
Article
Author: Hoxha, Bianka ; Bozo, Silvi ; Pojani, Eftiola ; Capparelli, Elena
Introduction:
Human papillomavirus (HPV) infection is a widespread skin-to-skin transmitted infection that poses a global health concern. Although Albania faced prior challenges, it has recently introduced a quadrivalent recombinant HPV vaccine, a critical step in preventing cervical cancer among young women. This study aims to identify potential gaps in knowledge and attitudes among Albanian women regarding cervical cancer and HPV infection, as well as provide insights into the effectiveness of the national primary prevention program.
Methods:
We conducted a cross-sectional study among 473 Albanian women using an anonymous online questionnaire to collect sociodemographic information, awareness on HPV infection and cervical cancer, and HPV vaccination practices. The association between sociodemographic variables and outcome measures was explored using descriptive statistics and Chi-square tests in SPSS.
Results:
Most of the participants fell within the age range of 18 to 30 years old (42.1 %). 71.7 % of the respondents lived in urban areas. According to the study findings, a considerable proportion of the participants demonstrated knowledge of cervical cancer, with 66.6 % correctly identifying HPV infection as a major cause of this disease. Additionally, the study uncovered that a substantial number of participants had an acceptable awareness (59.6 %) about the HPV vaccine. Nevertheless, 48.4 % of the participants expressed concerns about the vaccine's efficacy and safety.
Conclusions:
The study reveals knowledge gaps and misconceptions about HPV transmission, hereditary aspects, and its connection to various cancers. While a positive attitude towards preventive measures exists, concerns about HPV vaccination safety and efficacy underscore the need for targeted education campaigns to enhance awareness and accessibility, addressing misconceptions and promoting informed decision-making for effective cervical cancer prevention.
01 Nov 2016Urologiia (Moscow, Russia : 1999)
[Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)].
Article
Author: Zhestkov, A V ; Pakhomov, D V ; Vekhova, E V ; Ryzhov, A A ; Shmitko, A D ; Lipatov, I S ; Kostinov, M P ; Protasov, A D ; Tezikov, Yu V ; Blagovidov, D A
AIM:
To evaluate the effectiveness of combined use of the imiquimod 5% cream and vaccination against human papillomavirus (HPV) using a quadrivalent recombinant vaccine to achieve long-term clinical remission of chronic HPV infection manifested by anogenital warts.
MATERIAL AND METHODS:
The study comprised 36 patients, including 22 men, aged 26.4+/-4.1 years, who had from 1 to 5 anogenital warts. Participants of the study were vaccinated by quadrivalent recombinant vaccine under a 3-dose scheme 0-2-6 months co-administered with imiquimod 5% cream three times per week up to 16 weeks. The follow-up period was 2 years.
RESULTS:
Complete disappearance of genital warts within 1 year from baseline was observed in 34 (94.4%) patients. Two patients with anogenital warts after 1 year were treated for 1 year 3 months and 1 year and 4 months with Solcoderm which lead to the complete disappearance of genital warts. There were no recurrences of genital warts during the 2 years of follow-up.
CONCLUSION:
Vaccination with a recombinant quadrivalent vaccine concurrently with using imiquimod 5% cream results in prolonged clinical remission of chronic HPV infection manifested by anogenital warts in at least 94.4% of the cases (2 year follow-up).
01 Mar 2011The Journal of the American Osteopathic Association
Getting to know human papillomavirus (HPV) and the HPV vaccines.
Review
Author: Travis, Lisa ; Smith, Gregory D
More than 100 types of human papillomavirus (HPV), of which more than 40 are transmitted sexually, affect men and women. The worldwide prevalence of cervical HPV infection is approximately 10%. The most common HPV types worldwide are 16 and 18, which are the main causative viruses for cervical cancer and are both preventable by vaccination. Two HPV vaccines are currently approved in the United States: the quadrivalent HPV recombinant vaccine in males and females and the bivalent HPV recombinant vaccine in females. The Advisory Committee on Immunization Practices does not recommend routine use of the quadrivalent vaccine in males. The vaccines have been demonstrated to be highly effective in preventing cervical dysplasia, vulvar cancer, and genital warts related to HPV types 6, 11, 16, and 18; they are most effective, however, in vaccinees who have never been infected with HPV. Based on a review of the literature, the authors argue that it may be appropriate to routinely vaccinate both males and females to prevent the spread of HPV types 6, 11, 16, and 18.
100 Deals associated with Quadrivalent HPV recombinant vaccine (Shanghai Bovax Biotechnology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Androgen-Insensitivity Syndrome | Phase 3 | China | 09 Dec 2022 | |
| Vaginal intraepithelial neoplasia | Phase 3 | China | 09 Dec 2022 | |
| Vulvar intraepithelial neoplasia | Phase 3 | China | 09 Dec 2022 | |
| Condylomata Acuminata | Phase 3 | China | 15 Sep 2021 | |
| Uterine Cervical Cancer | Phase 3 | China | 15 Sep 2021 | |
| Uterine Cervical Dysplasia | Phase 3 | China | 15 Sep 2021 | |
| Vagina Carcinoma | Phase 3 | China | 15 Sep 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free